The Judy Gelfand Alzheimer Research Fund Sets Record in Fundraising for the Alzheimer's Association
The Judy Gelfand Alzheimer Research Fund, which benefits the Alzheimer's Association's research program, has raised more than $2 million since its inception six months ago. "The Judy Fund," established by Marshall M. Gelfand of Palm Springs, Calif., in honor of his wife, is the fastest growing individual named fund in the Alzheimer's Association's history.
"It is terrific to see so many friends, associates and caring community members get involved and make such generous donations in Judy's name," said Gelfand, founding partner of Gelfand, Rennert & Feldman, LLP and member of the Alzheimer's Association's Board of Directors. "Judy influenced so many people with her rich human connection. She did so much for the community and now in response the community is coming together to stop this disease. We know research is the key."
Judy Gelfand was diagnosed with Alzheimer's disease in 1995. She is known for prominent community leadership in Palm Springs and is the mother of three children, Todd, Elizabeth and Dean. Gelfand, Rennert & Feldman is the largest international business management firm representing clients in the fields of music, motion pictures and television.
"I share a common goal with the Gelfand family of wanting to live in 'a world without Alzheimer's disease," said author and playwright Herman Wouk. "I have known the brilliant and lovely Judy Gelfand for many years, and I have seen how this disease erodes the power of the brain.
Funding a cure should be the priority of our advanced culture. It's a privilege to contribute to the Alzheimer's Association, for research that could lead to finding better treatments, preventions and a cure."
Each year, the Alzheimer's Association and The Judy Fund will collaborate to sponsor specific projects that focus on pursuing new and promising avenues of research. Potential projects include investigations into the possible causes of the disease as well as the impact of cultural, behavioral, social and environmental factors on disease progression.
This year, The Judy Fund is sponsoring Edward H. Koo, M.D. at the University of California at San Diego. Dr. Koo and his colleagues hope their research will reveal previously unidentified targets in the brain for drug therapies.
"We're ecstatic with the Gelfand family's dynamic and rapid fundraising efforts," said Sheldon Goldberg, president and CEO of the Alzheimer's Association. "We commend Marshall Gelfand and the other contributors as they champion the Association's commitment to delay symptoms and eventually prevent Alzheimer's disease."
For more information, or to contact Alzheimer's Association, see their website at: www.alz.org
|Email Article To A Friend||Link to us!|